Procyrion is dedicated to improving outcomes for patients with cardiac and renal impairment using its catheter-deployed pump technology to address conditions with significant unmet needs. Aortix™ is a percutaneous mechanical circulatory support device that treats cardiorenal syndrome with a rapidly-deployed intra-aortic catheter-based system.

Aortix™ is currently in the research and development phase and is not available for sale in any country.
(Caution: investigational device. Limited by federal law to investigational use.)

Scientific Health Development Partners

Aquinas

Jefferson River Capital

BlueBird Merchant Ventures

Fannin Innovation Studio

Houston Angel Network

Procyrion, Inc.

Our DRAIN-HF trial evaluating the #Aortix pump for acute decompensated #heartfailure patients is well underway. Congrats to Henry Ford Hospital and John Muir Hospital for enrolling multiple patients in this important study! 

#clinicaltrials #cardiorenalsyndrome #diureticresistance #innovation

Another DRAIN-HF site begins patient enrollment! Congrats to Dr. Miguel Alvarez Villela and the Northwell Health Lenox Hill team on enrolling your first patient in this groundbreaking trial for #heartfailure patients. 
 
#clinicaltrials #cardiorenalsyndrome #diureticresistance #Aortix #innovation

BREAKING NEWS: We are proud to be recognized as a #Fierce15 Medtech company this year! Check out the interview with our CEO Eric Fain to learn more about our innovative Aortix technology and the potential it has to change the way patients with acute decompensated #heartfailure and cardiorenal syndrome are treated.

https://lnkd.in/gR47YYhU

First DRAIN-HF enrollment in the Bay Area! Congrats to Dr. Andrew Dublin, Dr. Wayland Lim and the team at John Muir Health on enrolling your first patient in this groundbreaking trial of Aortix for #heartfailure patients.  
#clinicaltrials #cardiorenalsyndrome #diureticresistance

Our President & CEO Eric Fain had the opportunity to connect with Tom Salemi, host of the DeviceTalks podcast, earlier this week. Eric details how our recent $57.7 million round will help us in our quest to make the company's innovative Aortix technology available to physicians and patients with acute decompensated heart failure and cardiorenal syndrome. 
https://bit.ly/3SvX7HD

Developer of implantable technology for hypertension and heart failure

CVRx

Developer of medical devices for heart failure

Sequena Medical

Procyrion, Inc. is a medical device company focused on developing the world's first catheter-deployed heart pump, known as the Aortix system. This innovative technology is designed to assist heart function and improve clinical outcomes for patients with heart failure.

Procyrion

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	May 8, 2024 9:03 AM	a46ff4c0
public peers	general	May 8, 2024 9:03 AM	11fc1b76
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	May 8, 2024 9:03 AM	224d68a4
company summary	general
signals	general
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general
news basic	general	May 8, 2024 9:03 AM	7f46345f
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:PROCYRION

Procyrion